Schwind eye-tech-solutions announced that its Amaris eximer lasers have been installed in 100 countries with more than 6 million treatments performed to date. With 3.1 million treatments (52 percent), LASIK performed with a femtosecond laser or a microkeratome is the most frequently chosen method by Schwind users since the introduction of the Amaris. Of these, 1.3 million treatments were performed as FemtoLASIK. In addition, the touchless TransPRK/SmartSurfACE procedure is enjoying growing demand. Around 1.5 million treatments have been performed since 2010, which is 25 percent of the total treatment volume with the Amaris product family.
The treatment analysis of procedures chosen by Schwind users since January 2018 shows the following trend: 54 percent of all Amaris treatments are performed as intrastromal procedures, 38 percent of them as femtoLASIK, and 16 percent as LASIK using a microkeratome. With a share of 32 percent, almost a third of treatments performed are with TransPRK/SmartSurfACE. The classic surface treatments PRK and LASIK add up to 14 percent.
In addition to the comprehensive refractive treatment options, Amaris offers safe and precise planning for therapeutic procedures, according to a company news release. The PTK-CAM module is based on phototherapeutic keratectomy (PTK) and addresses superficial refractive-neutral ablation, as well as deep ablation for perforating laser-assisted keratoplasty with the KPL option.
More than 240 peer-reviewed articles have been published by Amaris users so far and consistently reflect the success story of the Schwind excimer laser product family.